the fy20 defense appropriations act provides $40 million (m) to the department of defense spinal cord injury research program (scirp) to support innovative, high-impact spinal cord injury (sci) research¹.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 scirp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

applications submitted to the fy20 scirp must address one or more of the following focus areas:

• preserving and protecting spinal cord tissue at time of injury for improved neurologic outcomes
• identifying and validating biomarkers for diagnosis, prognosis, and for evaluation of treatment efficacies (translational research award and investigator-initiated research award only)
• bowel, genitourinary, cardiopulmonary dysfunction, and neuropathic pain
• psychosocial issues relevant to people with sci, their families, and/or their care partners

rehabilitation and regeneration—maximizing the function of the residual neural circuitry, including harnessing

• neuroplasticity and recovery to improve function after sci

https://cdmrp.army.mil/funding/scirp

clinical trial award – preproposal due may 21, 2020

investigators at all academic levels (or equivalent)

• preproposal is required; application submission is by invitation only.
• fund phase 0, i, or ii clinical trials with the potential to have a major impact on treatment or management of sci.
• applications must include at least two individuals with lived sci experience as members of the research team.
• preclinical data required for all clinical trial applications.
• maximum funding of $3m for direct costs (plus indirect costs)
• maximum period of performance is 4 years

translational research award – preproposal due may 21, 2020

investigators at all academic levels (or equivalent)

• preproposal is required; application submission is by invitation only.
• fund translational research studies that accelerate the movement of promising ideas in sci research into clinical applications.
• applications must include at least one individual with lived sci experience as a member of the research team.
• the scirp tra may include a pilot clinical trial as part of the proposed research where limited clinical testing of a novel intervention or device is necessary to inform the next step in the continuum of translational research.
• preliminary data required.
  • maximum funding of $1.25m for direct costs (plus indirect costs)
  • maximum period of performance is 3 years

investigator-initiated research award – preproposal due may 21, 2020

investigators at all academic levels (or equivalent)

• preproposal is required; application submission is by invitation only.
• fund and phase of sci-related research from basic through translational that has the potential to make an important contribution to sci research, patient care, and/or quality of life.
• clinical trials not allowed.
• preliminary data required.
• maximum funding of $500,000 for direct costs (plus indirect costs)
• maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the scirp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507
help@ebrap.org

the fy20 defense appropriations act provides funding to the department of defense peer reviewed cancer research program (prcrp) to support innovative, high-impact cancer research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 prcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

congressionally directed topic areas:  the prcrp appropriation of $110,000,000 will provide funds for research into cancers not addressed in the breast, pancreatic, prostate, ovarian, kidney, lung, melanoma, and rare cancer research programs.  to be considered for funding, applications for the fy20 prcrp must address at least one of the fy20 prcrp topic areas as directed by congress.  research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, melanoma, pancreatic, rare cancer, or ovarian cancer will not be accepted. the inclusion of the individual rare cancer research program shall not prohibit the prcrp from funding the below mentioned cancers or cancer subtypes that may be rare by definition.

the fy20 prcrp topic areas are:

^†as derived from the nci dictionary of cancer terms (http://www.cancer.gov/publications/dictionaries/cancer-terms).  immunotherapy is a type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer.  cancers studied under this topic area should be within the scope of the congressional language and the intent of the program announcement(s).

*national cancer institute (nci) definition of adolescents and young adults (https://www.cancer.gov/types/aya) is people between 15-39 years of age.  cancers studied under this topic area should be within the scope of the congressional language and the intent of the program announcement(s). research should be targeted toward children (ages 0-14 years), adolescents (ages 15-24 years), and/or young adults (ages 25-39 years).

^ǂmetastatic cancer is cancer that has spread from its original location to another place in the body, representing what is known as stage iii and stage iv cancer diagnoses.  while recent research has revealed that there is a genetic basis for susceptibility or resistance to metastasis, more research is needed to develop a comprehensive understanding of this complex process. applications to the metastatic cancer topic area should focus on the process of metastasis and not the cancer type (i.e.an agnostic interrogation of the process of metastasis).

the fy20 prcrp military health focus areas are listed below:

it is central to the vision and mission of the prcrp that applications address how the proposed research is related to military health, mission readiness, and the cancer health needs of both deployed and non-deployed military personnel, their dependents, veterans, and other military beneficiaries (i.e., family members of retirees).  the fy20 prcrp requires all applications to answer at least one of the following military health focus areas:

• environmental/exposure risk factors associated with cancer
• mission readiness

o    gaps in cancer prevention, early detection/diagnosis, prognosis, and/or treatment that may affect the general population but have a particularly profound impact on the health and well-being of military service members, veterans, and their beneficiaries

o    gaps in quality of life and/or survivorship that may affect the general population but have a particularly profound impact on the health and well-being of military service members, veterans, and their beneficiaries

https://cdmrp.army.mil/funding/prcrp

virtual cancer center director award – letter of intent due july 30, 2020

investigator at or above the level of associate professor (or equivalent); must have a proven publication and funding record in cancer research. 

deputy director must be at or above the level of associate professor (or equivalent); must have a proven publication and funding record in cancer research. deputy director must be at a different institution and must be in a different cancer discipline than the director.

• letter of intent is required.  an invitation to submit a full application is not required.
• supports visionary individuals who are established cancer researchers with a strong record of mentoring and commitment to leadership.
• the prcrp virtual cancer center director award is an opportunity to establish a virtual cancer center focused on fostering the next generation of independent cancer researchers across the spectrum of cancers included under the prcrp.
• director, with deputy director, will oversee the interactive virtual cancer center of early-career investigators (scholars) and their designated career guides, facilitate regular interactive communication among all members, and assess research progress and career progression of the scholars.
• early-career investigators interested in applying to the virtual cancer center should refer to the career development award – cancer center scholar option program announcement.
• maximum funding for the entire period of performance is $1,250,000 for direct costs (plus indirect costs).
• maximum period of performance is 4 years.

career development award – fellow option – letter of intent due july 30, 2020

principal investigator (pi): independent investigators at or above the level of assistant professor or instructor (or equivalent) and within 7 years after completion of their terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline.

career guide: investigators at or above the level of associate professor (or equivalent); must have a proven publication and funding record in cancer research. 

• letter of intent is required.  an invitation to submit a full application is not required.
• supports the addition of new early-career investigators (scholars) to be unique, interactive virtual cancer center focused on fostering the next generation of cancer researcher.
• previous nominal career development funding.
• a career guide – an experiences cancer research with cancer funding – is required.
• the career guide is not required to be at the same institution as the fellow.
• must address at least one of the fy20 prcrp topic areas.
• must address at least one of the fy20 prcrp military health focus areas.
  • preliminary data are not required.
  • clinical trials are not allowed.
  • maximum funding for the entire period of performance is $400,000 for direct costs (plus indirect costs).
  • maximum period of performance is 3 years.

career development award – cancer center scholar option – letter of intent due july 30, 2020

principal investigator (pi):  independent investigators at or above the level of assistant professor or instructor (or equivalent) and within 7 years after completion of their terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline.

career guide:  investigators at or above the level of associate professor (or equivalent); must have a proven publication and funding record in cancer research. 

• letter of intent is required.  an invitation to submit a full application is not required.
• supports the addition of new early-career investigators (scholars) to the unique, interactive virtual cancer center focused on fostering the next generation of independent cancer researchers.
• the scholar shall be required to interact within the virtual cancer center and with the cancer center director and deputy director.
• the scholar option will be required to interact within the virtual cancer center and with the cancer center director and deputy director.
• the scholar option provides intensive mentoring, national networking, and a peer group for junior faculty.
• scholars must demonstrate significant accomplishments.
• scholars whose ability to commit to conducting cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
• a career guide – an experienced cancer researcher with cancer funding – is required.
• the career guide is not required to be at the same institution as the scholar.
• must address at least one of the fy20 prcrp topic areas.
• must address at least one of the fy20 prcrp military health focus areas.
• preliminary data are not required.
• clinical trials are not allowed.
  • maximum funding for the entire period of performance is $800,000 for direct costs (plus indirect costs).
  • maximum period of performance is 4 years.

behavioral health science award – letter of intent due july 30, 2020

independent investigator with a faculty-level appointment (or equivalent).

• letter of intent is required.  an invitation to submit a full application is not required.
• supports innovative research and high-reward studies that span the spectrum of behavioral health science including prevention, quality of life, symptom management, resilience, and psychosocial issues related to cancer diagnosis, treatment, and survivorship.
• emphasis on innovation and military health/impact.
• must address at least one of the fy20 prcrp topic areas.
• must address at least one of the fy20 prcrp military health focus areas.
  • preliminary data may be required if proposing a pilot clinical trial.
  • pilot clinical trials are allowed.
  • maximum funding for the entire period of performance is $1,000,000 for direct costs (plus indirect costs).
  • maximum period of performance is 4 years.

translational team science award – letter of intent due july 30, 2020

at least two, and a maximum of three, pis must partner in one overarching correlative or translational research study.

at least one of the pis is encouraged to be a military or us department of veterans affairs investigator.

• letter of intent is required.  an invitation to submit a full application is not required.
• emphasizes multi-pi, multidisciplinary collaborations.
• supports translational studies associated with an ongoing or completed clinical trial that can lead to a future clinical trial or clinical application in cancer research relevant to service members, their families, and other military beneficiaries.
• not intended to support high throughput screenings, sequencing, etc.
• must address at least one of the fy20 prcrp topic areas.
• must address at least one of the fy20 prcrp military health focus areas.
• preliminary data are required.
• clinical trials are allowed.
• maximum funding for the entire period of performance is $1,500,000 for direct costs (plus indirect costs).
• maximum period of performance is 4 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the prcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the fy20 defense appropriations act provides funding to the department of defense peer reviewed cancer research program (prcrp) to support innovative, high-impact cancer research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 prcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

congressionally directed topic areas:  the prcrp appropriation of $110,000,000 will provide funds for research into cancers not addressed in the breast, pancreatic, prostate, ovarian, kidney, lung, melanoma, and rare cancer research programs.  to be considered for funding, applications for the fy20 prcrp must address at least one of the fy20 prcrp topic areas as directed by congress.  research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, melanoma, pancreatic, rare cancer, or ovarian cancer will not be accepted. the inclusion of the individual rare cancer research program shall not prohibit the prcrp from funding the below mentioned cancers or cancer subtypes that may be rare by definition.

the fy20 prcrp topic areas are:

^†as derived from the nci dictionary of cancer terms (http://www.cancer.gov/publications/dictionaries/cancer-terms).  immunotherapy is a type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer.  cancers studied under this topic area should be within the scope of the congressional language and the intent of the program announcement(s).

*national cancer institute (nci) definition of adolescents and young adults (https://www.cancer.gov/types/aya) is people between 15-39 years of age.  cancers studied under this topic area should be within the scope of the congressional language and the intent of the program announcement(s). research should be targeted toward children (ages 0-14 years), adolescents (ages 15-24 years), and/or young adults (ages 25-39 years).

^ǂmetastatic cancer is cancer that has spread from its original location to another place in the body, representing what is known as stage iii and stage iv cancer diagnoses.  while recent research has revealed that there is a genetic basis for susceptibility or resistance to metastasis, more research is needed to develop a comprehensive understanding of this complex process. applications to the metastatic cancer topic area should focus on the process of metastasis and not the cancer type (i.e.an agnostic interrogation of the process of metastasis).

the fy20 prcrp military health focus areas are listed below:

it is central to the vision and mission of the prcrp that applications address how the proposed research is related to military health, mission readiness, and the cancer health needs of both deployed and non-deployed military personnel, their dependents, veterans, and other military beneficiaries (i.e., family members of retirees).  the fy20 prcrp requires all applications to answer at least one of the following military health focus areas:

• environmental/exposure risk factors associated with cancer
• mission readiness

o    gaps in cancer prevention, early detection/diagnosis, prognosis, and/or treatment that may affect the general population but have a particularly profound impact on the health and well-being of military service members, veterans, and their beneficiaries

o    gaps in quality of life and/or survivorship that may affect the general population but have a particularly profound impact on the health and well-being of military service members, veterans, and their beneficiaries

https://cdmrp.army.mil/funding/prcrp

idea award – preproposal due may 14,  2020

independent investigator with a faculty-level appointment (or equivalent).

• preproposal is required; application submission is by invitation only.
• supports innovative, untested, high-risk/
  potentially high-reward concepts, theories, paradigms, and/or methods in cancer research relevant to service members, their families, and other military beneficiaries.
• emphasis on innovation and military health/impact.
• must address at least one of the fy20 prcrp topic areas.
• must address at least one of the fy20 prcrp military health focus areas.
• preliminary data are not required.
• clinical trials are not allowed.
• maximum funding for the entire period of performance is $500,000 for direct costs (plus indirect costs).
• maximum period of performance is up to 3 years.

impact award – preproposal due may 14, 2020

independent investigators at or above the level of assistant professor (or equivalent) are eligible to submit an application.

• preproposal is required; application submission is by invitation only.
• supports hypothesis-driven, high impact research.
• encourages applications that support research projects or ideas that specifically focus on critical scientific and clinical cancer issues, which, if successfully addressed, have the potential to make a major impact on one of the fy20 prcrp topic areas.
• must address at least one of the fy20 prcrp topic areas.
• must address at least one of the fy20 prcrp military health focus areas.
• preliminary data are required.
• clinical trials are allowed.
  • maximum funding for the entire period of performance is $1,000,000 for direct costs (plus indirect costs).
  • maximum period of performance is 3 years.

the fy20 defense appropriations act provides funding to the department of defense tick-borne disease research program (tbdrp) to support innovative, high-impact tick-borne disease research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 tbdrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website

applications submitted to the fy20 tbdrp must address one or more of the following focus areas:

• diagnosis:
  • sensitive and specific direct detection diagnostic assay for borrelia and/or other tbd pathogens.  assay should ultimately be amenable for implementation in a typical clinical setting, cost-effective, and rapid (diagnosis in < 24 hours).
  • diagnostic biomarker panel for lyme disease and other tbds that distinguishes tbd infection from other febrile illnesses.
  • approaches for lyme disease or other tbd diagnosis capable of distinguishing active infection and previous exposure, and/or monitoring response to treatment.
  • innovative and new approaches that provide diagnosis for a single or multiple tbd infections from a single sample.
• treatment: 
  • therapeutic strategies for treating acute and persistent tbds.  novel therapeutics and/or non-antibiotic modalities for treating tbds are encouraged.
  • in vitro interrogation of potential treatments designed to mitigate development of long-term sequelae following infection with bacterial, parasitic, or viral tick-borne (tb) agents.
• immunomodulatory approaches to treat the inflammatory response to infection.
• prevention: 
  • drugs, antibodies, or other novel approaches that can be administered and/or utilized prophylactically to prevent human tbd infection.
  • safe and effective human vaccines for tbds.
  • identification, validation, and/or improvement of tick- or reservoir-targeted prevention and control interventions.
  • understanding the ecology of understudied tbd vectors and reservoirs with emphasis on how it relates to human risk.
• pathogenesis:
  • pathogenesis of persistent clinical manifestations associated with lyme disease.
  • immune evasion and/or tolerance of tb pathogens (lyme and/or other tbds).
  • effects of tick sialome on human infection, immune response, disease progression, and pathogen dissemination.
  • tb infections and co-infections (simultaneous or sequential) and their effects on human disease severity, the local and systemic immune response, and/or pathogen synergy and competition.
  • red meat allergy (allergic response to alpha-gal).

https://cdmrp.army.mil/funding/tbdrp

career development award – preproposal due may 27, 2020

principal investigator (pi): 

early-career research scientist, physician scientist, or other qualified clinical scientist, within 10 years of completion of his/her terminal degree (excluding time in residency or on family medical leave) at the time of submission, working to become independent investigators who exhibit a strong desire to pursue careers in tick-borne disease research; time spent as a postdoctoral fellow is not excluded

mentor:  independent investigators at or above the level of associate professor (or equivalent); must have a recent (last 5years), proven funding and publication record in tick-borne disease research.

the pi and mentor do not need to be located with the same organization.

• to fund early-career investigators to conduct impactful research under the mentorship of an experienced tick-borne disease researcher.
• career development plan is required.  plan should be prepared with appropriate guidance from the mentor, should clearly articulate a strategy for acquiring the necessary skills, competence, and expertise to establish a career at the forefront of tick-borne disease research, and should outline how the pi will gain experience in tick-borne disease research.  pi’s institution must demonstrate a commitment to the pi through a minimum of 75% protected research time for tick-borne disease research.  the application must include clearly stated plans for interactions and communication coordination between the pi and mentor.
• preliminary data is encouraged, but not required.
• clinical trials are not allowed.
• maximum funding of $300k for direct costs (plus indirect costs)
• maximum period of performance is 3 years

idea development award – preproposal is due may 27, 2020

independent investigators at or above the level of assistant professor (or equivalent)

• to fund research that could lead to impactful discoveries or major advancements that will accelerate progress in improving outcomes for individuals affected by lyme diseases and/or other tick-borne illnesses
• research should be conceptually innovative, exhibit high levels of creativity, or challenge existing research paradigms.
• applications must describe the short- and long-term impact of the proposed research, as well as the public health burden of the diseases being addressed.
• preliminary data is encouraged, but not required.
• clinical trials are not allowed; human studies/clinical research are permitted.
• maximum funding of $600k for direct costs (plus indirect costs)
• maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the tbdrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the fy20 defense appropriations act provides funding to the department of defense prostate cancer research program (pcrp) to support innovative, high-impact prostate cancer research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 pcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

the mission of the fy20 pcrp is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of service members, veterans, and all the men and their families who are experiencing the impact of the disease.  within this context, the pcrp is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care, with an emphasis on investing in research that will benefit patients diagnosed with lethal prostate cancer or improve quality of life for men diagnosed with this disease.  all applications are required to address one or more of the following fy20 pcrp overarching challenges: 

• improve the quality of life for survivors of prostate cancer
• develop treatments that improve outcomes for men with lethal prostate cancer

applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease, etc.

• reduce lethal prostate cancer in people of african descent, veterans, and high-risk or underserved populations

high-risk populations include, but are not limited to, people of african descent (including caribbean americans), genetically predisposed populations, service members, and veterans.  underserved populations include, but are not limited to, men with limited access to clinical care and resources (in both rural and urban settings), and sexual and/or gender minorities with, or at risk for, prostate cancer.

• define the biology of lethal prostate cancer to reduce death

applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease; etc.  applications should not focus on topics such as differentiation between low risk and intermediate risk prostate cancer.

https://cdmrp.army.mil/funding/pcrp

early investigator research award – letter of intent due june 4, 2020

by march 31, 2021, postdoctoral principal investigators (pis):

• must possess a doctoral degree (or equivalent)

have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training)

• supports research opportunities focused on prostate cancer for individuals in the early stages of their careers.

pis must have a designated mentor who is an experienced prostate cancer researcher.

must address at least one of the fy20 pcrp overarching challenges.

• maximum funding of $300,000 for direct costs (plus indirect costs).
• maximum period of performance is 2 years.

physician research award – letter of intent due june 4, 2020

at the time of application submission, the pi must be either:

• in the last year of an accredited graduate medical education program, either as a resident or fellow;

or

within 5 years of having initiated a faculty appointment (including instructor positions)

• supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research.
• pis must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.
• pis must have a designated mentor with an established research program in prostate cancer.
• must address at least one of the fy20 pcrp overarching challenges
• maximum funding of $750,000 for direct costs (plus indirect costs).
• maximum period of performance is 4 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the pcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the objective of the idea to innovation (i2i) grants is to accelerate the pre-competitive development of promising technology originating from the university and college sector and promote its transfer to a new or established canadian company. the i2i grants provide funding to college and university faculty members to support research and development projects with recognized technology transfer potential. this is achieved through defined phases by providing crucial assistance in the early stages of technology validation and market connection.

the annual synergy awards for innovation recognize examples of collaboration that stand as models of effective partnership between industry and colleges or universities.

this call for proposals is soliciting applications for collaborative projects, workshops or training courses in the area of security-related civil science, technology, innovation, and beyond. the sps programme provides support and expert advice for security-relevant activities in the form of four established grant mechanisms: multi-year projects (myp), advanced research workshops (arw), advanced training courses (atc), and advanced study institutes (asi). interested applicants should develop proposals for activities that fit within one of these formats. details on where to find application instructions and templates can be found below in the section “programme requirements”. participation in the sps programme enables experts and scientists to develop innovative solutions to today’s security challenges, and to build partnerships with their peers in nato and partner nations. applications are to be jointly prepared by scientists or experts from at least one nato and one partner nation, and be linked to nato’s strategic objectives. proposals shall specifically respond to one or more of the sps key priorities as detailed in the next section. note: sps supports projects in the field of security-related civilian science and/or related to dual-use applications. proposals that have pure military objectives should be addressed to different programmes, in particular the nato science and technology organization (sto) collaboration support office (cso).

the law foundation of ontario invites applications from nonprofit organizations across canada to the access to justice fund (atjf) for projects relating to:

• public legal education, triage, brief services, and referrals (including tools to assist self-represented litigants)
• indigenous peoples’ legal needs
• refugees

grants made from the atjf are to be used to support public access to justice. while the phrase “access to justice” cannot have a single meaning, it is closely linked to the promotion of equity, fairness, and the elimination of barriers to justice (whether physical, psychological, financial, linguistic, or social). it can include access to information by low-income or marginalized persons so that they can understand their options with respect to legal problems and services and act on those options.

the foundation encourages project proposals aimed at addressing the diverse needs of canadians, including those living in rural and remote areas. collaborations among organizations with different areas of expertise and from different areas of the country are also encouraged.

the proposed project may be local, regional, provincial or national in scope. in making grants from the atjf, the foundation wishes to support high-quality projects that have the potential to bring real improvements to the communities served.

the canadian glycomics network (glyconet) is a network of centres of excellence that focuses on the role of glycans (carbohydrates) in health. areas of focus are neurodegenerative diseases, infectious diseases, chronic diseases, in particular diabetes & obesity, genetic diseases involving errors in glycan metabolism, and cancer. additional information about network research can be found at www.glyconet.ca. a key goal of glyconet is the translation of research advances into novel products for treating disease. accordingly this request for proposals seeks to fund more mature projects needing network support to de-risk and advance them to a state at which translation is possible.

these grants fund partner-led initiatives to advance a partner challenge. maximum request: $150,000 for one year, with possibility of one year renewal, 1:1 matching required.